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Introduction
Hypertension remains a major cause of heart disease and stroke, with approximately 1 in 3 U.S. adults currently diagnosed as hypertensive and a further 6-10% of Americans estimated to have undiagnosed hypertension. 1 In addition, a significant proportion of those with diagnosed hypertension have poorly controlled blood pressure (BP). 2, 3 Thus, there is a need to identify persons at risk either for progressing to clinically overt hypertension or for developing complications of this disease. In particular, BP control can be improved by more aggressive lifestyle and dietary changes in those with both prehypertension and overt hypertension. 4 The onset of hypertension is an insidious process that typically occurs over many years and is often preceded by altered diurnal BP patterns and prehypertension. 5, 6 While hypertension is diagnosed using defined BP thresholds, risks associated with elevated BP occur on a continuous spectrum. Indeed, even early, pre-hypertensive, BP abnormalities can induce structural heart changes 7 , potentially affording the opportunity both to detect persons at risk for overt hypertension and to initiate timely preventive strategies. 8 Prior studies have focused on the association between subclinical structural heart disease, particularly left ventricular hypertrophy (LVH), and subsequent development of hypertension. While these studies have confirmed that baseline LVH, measured by both echocardiography 9, 10 and by cardiac MRI 11 , is associated with incident hypertension, these imaging modalities are often impractical and too costly for routine screening.
New highly sensitive cardiac troponin T (hs-cTNT) assays have great potential as noninvasive laboratory-based markers of subclinical myocardial damage. 12 These assays can detect subclinical myocardial damage in a significant proportion of persons who are free of known cardiovascular disease in the community. 13, 14 Interestingly, detectable levels of hs-cTNT and is often preceded by altered diurnal BP patterns and prehypertension. 5, 6 Whil il ile e e hy hy hype pe pert rt rten en ensi si sion s diagnosed using defined BP thresholds, risks associated with elevated BP occur on a cont t tin in inuo uo uous us us s s spe p p ct t tru ru um. Indeed, even early, pre-hyp yp yper er erte t nsive, BP abnorm m mal al alit i i ies can induce t t tru u uctural heart t t c c c a hang ng nges es e 7 7 7 , po po pote te tent nt ntia ia iall ll ly y y af af a fo ford d din in ing g g the e o o oppo po port rt rtun un nit it ity bo bo both th th t t to o o de d detect t t p p pe er erso so son ns ns a a at t t ri i isk sk sk f f for or or ov v ver er ert t t hypert t ten en ension on on and d d t t to in ni it i ia a ate t t ti i ime m m ly ly ly p pre e eve ve ventiv ve str r rat t tegi gi gies es es. 8 P P Pr ri rior or r st t tud dies s s h h have fo fo focus sed d d on n n th he as as asso so soci ci ciat at atio io ion n n be be betw t twee ee een n n su s subc bc bcli li lini ni nica ca cal l l st st stru r ruct ct ctur r ural al al h h hea ea eart rt rt d d dis is isea ea ease se se, pa pa part rt rtic ic icul l ular ar arly l ly l l lef ef eft t t ve e vent nt ntri ri ricu c cula la lar r r hy h hype pe pert rt rtro ro roph ph phy appear to be more strongly linked to structural heart disease and its risk factors than to epicardial coronary artery disease. [14] [15] [16] Thus, hs-cTNT screening may be of particular use in persons at risk for clinically apparent hypertension and other cardiovascular endpoints. Hs-cTNT may also help identify individuals who are at risk of developing hypertensive end-organ damage, such as LVH.
Thus, we sought to determine if hs-cTNT could identify persons at risk for subsequent hypertension or LVH in a large U.S. community-based cohort, the Atherosclerosis Risk in Communities (ARIC) Study.
Methods

Study Population
The ARIC Study is a prospective cohort of 15,792 participants enrolled between 1987 and 1989 from four U.S. communities (Forsyth Country, North Carolina; Jackson, Mississippi; Minneapolis, Minnesota; and Washington County, Maryland). 17 We measured hs-cTNT in samples collected from all participants at ARIC visit 2, which took place from 1990 to 1992 and represents the baseline for this current analysis. Of the 14,348 persons who attended visit 2, we excluded all persons with prevalent diagnosed hypertension (n=6,801), those who had coronary heart disease (CHD, including silent myocardial infarction detected by electrocardiogram [ECG]), stroke, or heart failure at or prior to visit 2 (n=194), or those who were missing variables of interest (n=837) (eFigure 1). Thus, 6,516 persons were included in the main analysis evaluating our primary outcome of incident diagnosed hypertension (self-report of diagnosis or medication use during annual telephone follow-up). In our secondary analysis of incident visit-based hypertension, we excluded 599 persons with measured BP at baseline >140/90 mmHg (elevated blood pressure) and 242 persons without available BP measurement data, for an analytic study sample of 5,675
The 
Measurement of hs-cTNT and other exposure variables
We measured hs-cTNT in stored serum samples, collected at visit 2, using the Roche highsensitivity Troponin T reagent kit, a sandwich immunoassay performed on a Roche Elecsys 2010
Analyzer (Roche Diagnostics, Indianapolis, Indiana) at the University of Minnesota in 2012-2013.
Intra-assay coefficients of variation (CVs) are 2.1% at a mean hs-cTNT concentration of 26 ng/L and 1.0% at 1990 ng/L. Inter-assay CVs are 6.0% at a mean hs-cTNT concentration of 25 ng/L and 3.7% at 1940 ng/L. The measurement range of the assay is 3-100,000 ng/L, the limit of blank is 3 ng/L and the lower limit of detection is 5 ng/L. The intra-individual reliability of hs-cTNT values have been demonstrated to be high among ARIC study participants (laboratory reliability r value=0.94, six week biological reliability r value=0.94). 18 Participants self-reported smoking status. Plasma lipid concentrations and body weight and height for body mass index (BMI) were determined using standardized protocols. Glucose was measured using the hexokinase method. 19 Diagnosed diabetes was defined as a self-reported physician diagnosis of diabetes or current use of diabetic medications. Glomerular filtration rate was estimated using serum creatinine and the CKD-EPI 2009 equation. 20 N-terminal pro-brain natriuretic peptide (NT-proBNP) was measured in stored serum samples from visit 2 on a Roche Elecsys 2010 Analyzer using a sandwich immunoassay method (Roche Diagnostics, Indianapolis, Indiana).
Follow-up for outcomes of interest
Participants were contacted annually via telephone, with follow-up currently available through March 2012. Incident diagnosed hypertension was assessed during these annual telephone calls 3.7% at 1940 ng/L. The measurement range of the assay is 3-100,000 ng/L, the lim m mit it it o o of f f bl bl blan an ank k k is is is 3 ng/L and the lower limit of detection is 5 ng/L. The intra-individual reliability of hs-cTNT values have e e b b bee ee een n n de de demo m m n ns nstr t t ated to be high among ARIC C s s stu tu tudy d participants (labo o orat a a ory reliability r R R v v valu u ue=0.94, si ix x x w we week k k b b bio o olo lo log gi gica ca cal l l re e eli li iab ab abil il ilit ty y r va va val lu l e= =0.94 4). ). ). 18 18 18 P P Pa ar arti i ici ci cipa pa pant nts s s se se s lf-rep ep epo o orte te ted d d sm sm smok ok okin in ing g g using the following questions: "Has a doctor ever said you had high blood pressure?", or "Since we last contacted you has a doctor said you had high blood pressure?", and "Did you take any medications during the past two weeks for high blood pressure?". After visit 2, ARIC participants also completed two further follow-up study examinations, visit 3 (1992-1995) and visit 4 (1996-1998) . During these follow-up study visits, BP was recorded as the mean of at least 2 seated measurements using a manual random-zero sphygmomanometer.
We also evaluated the association between hs-cTNT and a well-known sequela of hypertension, LVH. This secondary outcome was assessed at visits 3 and 4, in persons free of both hypertension and LVH at visit 2, using resting 12-lead electrocardiograms and defined by Cornell criteria.
21
Statistical Analyses
Characteristics for the study population were presented according to categories of hs-cTNT (<5, 5- 99th percentile value for a "healthy" reference group of persons aged 20-70 years. 22 We further divided persons with values between 5-13 ng/L into two categories using a cutoff at the mid-point of this range. 15 The primary outcome of interest was incident diagnosed hypertension during a maximum of 19.9 and a median of 12 years of follow-up. Incident cases were identified at ARIC study visits 3 and 4 and, thereafter, by annual telephone contact with all participants. Cases were defined as a self-reported diagnosis of hypertension or antihypertensive medication use after visit 2. Time of criteria.
21
Statistical Analyses
Char ar rac ac acte te teri ri rist st stic ic ics fo o or th t e study population were pres s sen en ente t t d according to cate eg ego o ories of hs-cTNT (<5, 5- We used Cox proportional hazards regression models for the primary outcome of diagnosed hypertension and discrete proportional hazards (cloglog) regression models for both secondary outcomes (visit-based incident hypertension or incident LVH) to estimate adjusted hazard ratios (HRs) for the association between baseline hs-cTNT and these outcomes. We modeled hs-cTNT as a categorical (<5 [reference], 5-8, 9-13, or 14 ng/L) and continuous exposure (log-transformed). In analyses with hs-cTNT as a continuous exposure, visit 2 hs-cTNT was modeled as untransformed or log-transformed and either truncated at <3ng/L (the limit of measurement) or with unmeasurable levels assigned a value of half the lower limit of measurement (1.5ng/L). 23 Using Martingale residuals to assess fit, the log-transformed hs-cTNT without truncating fit the continuous models best. P-values for linear trend among hs-cTNT categories were obtained by assigning the median hs-cTNT value in the above categories of hs-cTNT and modeling this ordinal variable continuously. For all models, we verified the proportionality of the hazards with Schoenfeld residuals.
1998) among persons free from both hypertension and LVH at visit 2 (1990-1992) . . .
We used Cox proportional hazards regression models for the primary outcome of diag g gno no nose se sed d d hy hy hype p p rt t ten n nsion and discrete proportional l l ha ha haz z zards (cloglog) regre es essi s s on models for both , current lipid-lowering medication use (yes or no), LVH (yes or no), and diagnosed diabetes (yes or no). We tested for interactions by age, sex, and race. Model discrimination was assessed using Harrell's C-statistic 24 , and we evaluated improvement in the Cstatistic for the addition of hs-cTNT as a log-transformed continuous variable to the fully adjusted model. Furthermore, for the primary outcome of diagnosed hypertension, we calculated the continuous net reclassification index (NRI) statistic 25 , also based on the addition of hs-cTNT to the full model.
In sensitivity analyses we additionally adjusted for baseline (visit 2) BP or NT-proBNP levels. Because baseline hs-cTNT is associated with all-cause mortality, cardiovascular death, and sudden cardiac death 14, 16, [26] [27] [28] , we also conducted sensitivity analyses with a competing risk regression method (Fine-Gray approach) using a cumulative incidence function to account for intervening deaths. 29 In addition, we also modeled hs-cTNT using linear splines in fully-adjusted Cox models for 
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Results
In our community-based study sample of subjects without a history of cardiovascular disease and free from baseline hypertension, persons with higher baseline hs-cTNT were more likely to be older, male, black, pre-hypertensive, obese, diabetic, and have reduced kidney function ( Table 1) .
Persons excluded due to missing values were not markedly different but were somewhat older, more likely to be black, and had a slightly more adverse health profile compared to those who were included in our study (eTable2).
During a maximum of 19.9 and a median 12 years of follow-up, 68% (n=4421) of the study sample developed our primary endpoint; incident diagnosed hypertension. Of these, 70% (n=3108)
had hs-cTNT <5 ng/L at baseline, 21% (n=936) had hs-cTNT 5-8 ng/L, 6% (n=281) had hs-cTNT 9-13 ng/L, and 2% (n=96) had hs-cTNT 14 ng/L ( Table 2 ). Crude incidence rates (per 1,000
person/years) of diagnosed hypertension were 54 in those with hs-cTNT <5 ng/L, 64 with hs-cTNT 5-8 ng/L, 73 with hs-cTNT 9-13 ng/L, and 74 in persons with baseline hs-cTNT 14 ng/L.
After multivariable adjustment, baseline hs-cTNT remained significantly associated with incident diagnosed hypertension ( Table 2) . Specifically, relative to those with undetectable hscTNT at baseline, persons in the higher categories of hs-cTNT had a higher adjusted risk of hypertension. Similar results were found for log-hs-cTNT modeled as a continuous variable. A continuous and roughly linear association between baseline hs-cTNT and incident diagnosed hypertension is shown graphically in Figure 1a . Furthermore, for the primary outcome of incident diagnosed hypertension, the addition is hs-cTNT as a log-transformed continuous variable to our fully adjusted base model resulted in a significant increase in the C-statistic from 0.609 to 0.613 (p=0.003) and an improvement in continuous NRI of 20% (p=0.001). Results for the incident diagnosed hypertension outcome were not appreciably different in the sensitivity analysis that had hs-cTNT <5 ng/L at baseline, 21% (n=936) had hs-cTNT 5-8 ng/L, 6% (n=281) 1) 1) h h had ad ad h h hs-s s-cT cT cTNT N N 9-13 ng/L, and 2% (n=96) had hs-cTNT 14 ng/L ( Table 2 ). Crude incidence rates (per 1,000 pers son on on/y /y /yea ea ears rs rs) ) ) of d d dia ia iagnosed hypertension were 54 4 i i in n n th t t ose with hs-cTNT T <5 <5 <5 ng/L, 64 with hs-cTNT excluded persons with elevated BP at baseline (eTable 3).
The association between baseline hs-cTNT (both by category and as a continuous exposure) and our secondary outcome of incident visit-based hypertension was stronger than that for incident diagnosed hypertension (Table 2, Figure 1b) . Further, in analyses stratified by baseline BP category (normotensive or pre-hypertensive), we observed that the overall association between hs-cTNT and both incident hypertension outcomes appeared to be largely driven by more robust associations in persons who were normotensive at baseline (p-for-interaction=0.04 for diagnosed hypertension and p-for-interaction=0.001 for visit-based hypertension) ( Table 3 and eTable 4). Associations between hs-cTNT and both incident diagnosed and visit-based hypertension were largely unchanged after further adjusting for baseline BP or NT-proBNP (eTable 5). Interactions for the association of hs-cTNT and hypertension by age, gender, and race were all non-significant (all p-values-for-interaction >0.10).
There were 532 competing deaths for the primary outcome of incident diagnosed hypertension over 12-years median follow-up, but only 57 competing deaths for the secondary outcome of incident visit-based hypertension over 6-years. In competing risk models, the association between hs-cTNT and incident diagnosed hypertension remained significant but was somewhat weakened in the hs-cTNT 5-8 ng/L and 9-13 ng/L categories and was no longer significant in those with baseline hs-cTNT 14 ng/L ( Table 2 ). In contrast, results for the 6-year incident visit-based hypertension were similar in the Fine-Gray competing-risk models Finally, we found that, relative to hs-cTNT of <5ng/L, persons in higher categories of hscTNT had a highly significant 6-year risk of incident LVH by ECG: HR, 2.29 (95% CI 1.24-4.26) for hs-cTNT 5-8ng/L, HR, 2.94 (95% CI 1.14-7.58) for hs-cTNT 9-13ng/L and HR, 5.19
(95% CI 1.49-18.08) for hs-cTNT 14ng/L ( Table 4) .
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Discussion
In this large community-based study of U.S. adults, free of baseline hypertension and cardiovascular disease, we found that hs-cTNT was independently associated with subsequent development of hypertension, defined either by diagnosed cases (self-reported diagnosis or medication use) or by objective office measurement of BP, and also with incident LVH by ECG.
Findings were similar by age, race and gender categories. Our results suggest that chronic subclinical myocardial damage, detected by elevated hs-cTNT, may precede the development of hypertension in the general population and that this novel biomarker of cardiac damage may have utility for identifying persons at future risk for hypertension and hypertensive end-organ damage.
Prior studies have reported the cross-sectional association between established hypertension and prevalent hs-cTNT elevations 16, [30] [31] [32] . However, to our knowledge, this is the first study to evaluate the association between preceding subclinical myocardial damage, as measured by hs-cTNT, and subsequent risk of hypertension over prospective follow-up. This association was strongest for persons who had baseline normal BP readings (in contrast to those with pre-hypertension). Notably, the vast majority of individuals with prehypertension go on to develop hypertension, irrespective of baseline hs-cTNT. Therefore, the absolute risk of hypertension is very high in this entire sub-group, helping to explain why the relative impact of hs-cTNT for prediction of hypertension appeared non-significant in those with prehypertension.
While the exact pathway linking hs-cTNT to incident hypertension is unclear, a number of considerations are worth discussing. Elevated BP develops over time along a spectrum from normotension, to abnormal diurnal patterns of BP, to pre-hypertension, and then, ultimately, to clinical hypertension 5 . It is known that abnormalities in cardiac structure can occur long before damage.
Prior studies have reported the cross-sectional association between established hype pe pert rt rten en ensi si sion on on and d d p p prevalent hs-cTNT elevations 16, , 30 30 30-32 . However, to our r r kn k k owledge, this is the fi fi first t t study to eva va va u luat t te e e h th the e e as as asso so soci ci ciat at atio io on n n be b b t twee ee en n n pre ece e edin n ng g g su u ubc bc bcli i the diagnosis of overt hypertension is made in the clinic 5, 9, 33 . Based on our results, it is possible that these early BP aberrations cause myocardial damage, leading to elevated hs-cTNT, before clinically overt hypertension is recognized. Compatible with this hypothesis, it has been shown elsewhere that "non-dippers" (an abnormal diurnal BP pattern where sleep systolic BP fails to decrease >10% from daytime systolic BP and a known risk-factor for subsequent hypertension 6 ), are more likely to have prevalent detectable troponin levels by hs-cTNT assays 34 .
In addition, BP is highly variable and its true hemodynamic load cannot easily be captured by single office measurements (which are subject to misclassification error). Thus, it is also possible that the association between hs-cTNT and subsequent hypertension in ARIC could be a manifestation of the well-known phenomenon of "masked hypertension", the clinical condition in which a patient's office BP level is <140/90 mm Hg but home or ambulatory readings are in the hypertensive range 35 . Masked hypertension occurs in over 10% of the adult population 35, 36 and is known to result in end organ damage 37, 38 .
Further, we found that elevated hs-cTNT was also a risk factor for the development of LVH in persons without baseline hypertension or clinical cardiovascular disease (including silent MI). This suggests that hs-cTNT may also predict future sequelae of hypertension and is consistent with our hypothesis that elevated hs-cTNT may reflect occult BP abnormalities in some individuals. Indeed, prior case-control data suggest that hs-cTNT is also associated with subsequent albuminuria in hypertensive patients. 39 It is also worth noting that hs-cTNT could potentially be contributing more directly to the development of hypertension. For example, elevated hs-cTNT has been linked with arterial stiffness in diabetics 40 .
Our results were robust to multiple sensitivity analyses. Standard Cox proportionalhazards models assume that persons censored (including those censored for death) prior to the be a manifestation of the well-known phenomenon of "masked hypertension", the e e c c cli li lini ni n ca ca cal l l condition in which a patient's office BP level is <140/90 mm Hg but home or ambulatory ead din in ings gs gs a a are re re i i in th h he e e hypertensive range 35 . This analysis has some limitations. This study was observational and, thus, may be subject to residual confounding. The small proportion of persons who were excluded for missing values (12%) had a slightly worse health profile than those included in our study. We do not have ambulatory BP recordings to determine whether or not masked hypertension or abnormal diurnal values were present in persons with elevated hs-cTNT. Cases of diagnosed hypertension were identified by self-report of diagnoses or medication used during annually follow-up;
however, similar results were obtained in our analyses of visit-based hypertension (incorporating objectively elevated BP obtained during the clinical visit). Strengths of the study include the large sample size, bi-racial population, and rigorous measurement of cardiovascular risk factors.
In conclusion, elevated hs-cTNT in the general population, particularly among persons benefit from evaluation for masked hypertension and from more intensive lifestyle le le B B BP P P nterventions to reduce the likelihood of developing this morbid disease. Further research is nece e ess ss ssar ar ary y y to to to c c con n nfi fi fir r rm whether hs-cTNT could be e e u u use se eful in screening tho os ose e e at risk for h hy hyp pe p rtension. with normal blood pressure, identifies persons at risk for subsequent hypertension or LVH.
Further studies are necessary to determine whether subclinical myocardial damage in these settings is due to masked hypertension or abnormal diurnal variability in BP. Elevated hs-cTNT in low-risk ambulatory populations may prove to be clinically useful in identifying persons at risk for hypertension, affording the opportunity both to consider ambulatory blood pressure monitoring and to initiate more intensive preventive strategies. Undiagnosed hypertension (BP >140/90mmHg)* Table 1 . Linear ar r s s spl p p ines of hazard for h h hyp yp ypertension with ba ba back ck ckground d d dis s str tr trib ib ibut ut tio io iona na nal l l hi h h st st stog og ogra ra ram m m of of of b b bas s se e eli li lin n ne h hs---cTNT NT NT l l lev ev evel l ls, s, s, tru ru runc nc ncat at ated e at t t th th the e e 99 99 99 th p p pe e erce ce cent nt ntil il ile e e of f f h h hs s-s cTnT ( ( (18 1 1 n ng/ /L). P Person on ns s s wi w th h h h h hs---c cT c NT T T < < <3 ng ng g/L we we w re imp mp mpu u ute e ed val lu ues of of of 1.5 n n ng g/ g/L. N N Note th ha h h he e e "P P Pro ro ropo po port rt rtio io ion n n of of of t t the he he P P Pop op opul ul ulat at atio io ion" n n a a axi xi xis s s la la labe be bel l l id id iden en enti ti tifi fi fies es es t t the he he p p per er erce ce cent nt ntag ag age e e of of of t t the he he A A ARI RI RIC C C an an anal al alyt yt ytic ic ic by guest on July 25, 2017 eFigure 1. Flow Chart of exclusion process used to construct the main study sample used to assess the primary outcome of Diagnosed Hypertension, drawn from ARIC subjects free of baseline hypertension or cardiovascular disease ARIC participants who attended visit 2 (1990-1992) n = 14,348
Participants without hypertension or cardiovascular disease n = 7,353
Main Analysis Study population, n = 6,516
Participants with hypertension or cardiovascular events occurring at or prior to visit 2: 6801 with hypertension 194 with coronary heart disease (including silent MI by ECG), heart failure, or stroke 
